Quick Links

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps highlight key elements of the Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast Cancer online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology.

Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast Cancer

Release Date: January 30, 2017
Expiration Date: January 30, 2018
Media: Internet - based


Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Meeting is designed to provide a dynamic review of current and evolving paradigms in the treatment of HER2-positive breast cancer, including therapeutic decision-making in the adjuvant setting, biomarkers, extended adjuvant therapy, and management of treatment-related toxicities.

Our Program Chair, Joyce O'Shaughnessy, MD, and our expert faculty, William J. Gradishar MD, FASCO, FACP, Mark Pegram, MD, and Linda T. Vahdat, MD, MBA, emphasize the cutting-edge clinical research that is shaping how clinicians treat HER2-positive breast, now and in the not-too-distant future.

This online CME activity includes 2 segments, one on critical evaluation of landmark trials and the need for more effective adjuvant approaches and another on how emerging strategies can improve outcomes for patients with early stage HER2-positive breast cancer. Each segment will start with a brief didactic overview leading into an extensive panel discussion led by Dr. O’Shaughnessy. This extended discussion format will allow ample time for examining the nuances and challenges faced by clinicians in everyday practice, and include a discussion of strategies for applying emerging data to clinical practice to improve outcomes for patients. The activity will conclude with an evidence-based summary of key points discussed during the program.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology.

CME Activity Table of Contents

  • Welcome & Introductions
  • A Critical Evaluation of Landmark Trials: Assessing Long-Term Outcomes and the Need for More Effective Adjuvant Approaches
  • How Can Emerging Strategies Improve Outcomes in the Management of Early-Stage, HER2+ Breast Cancer?
  • Evidence-Based Summary and Conclusion
  • Sources


Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, "educational content/video files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical oncologists, pathologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Review landmark and recent trial data, along with unmet needs in the area of adjuvant therapy for HER2-positive breast cancer
  2. Discuss the application of biomarkers, molecular assays, and other risk assessment tools in treatment decision making for HER2-positive breast cancer
  3. Explain current standards and emerging approaches for the management of toxicities associated with extended adjuvant treatment of HER2-positive breast cancer
  4. Apply strategies for individualized treatment planning based upon efficacy and safety data, as well as patient and disease characteristics

Faculty, Staff, and Planners' Disclosures


Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
Co-Chair, Breast Cancer Research Program,
The US Oncology Network
Dallas, TX

Disclosure: Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Lilly, Johnson & Johnson, Merrimack Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi, Takeda, Medfusion.


William J. Gradishar MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Deputy Director, Clinical Network
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Director, Maggie Daley Center for Women's Cancer Care
Deputy Chief, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure: No relevant financial relationships with commercial interest to disclose.

Mark Pegram, MD
Director, Breast Cancer Oncology Program
Co-Director, Molecular Therapeutics Program
Stanford Cancer Institute
Palo Alto, CA

Disclosure: Consultant: Genentech.

Linda T. Vahdat, MD, MBA
Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York, NY

Disclosure: Grant/Research Support: Medivation, Pharmamar, Celldex Therapeutics, Immunomedics, Lilly, Eisai; Speakers Bureau: Eisai; Scientific Advisor: Berg Health.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 100
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705


Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By